GFATM: Globaler Fonds zur Bekämpfung von Aids, Tuberkulose und Malaria – Core Contribution

The GFATM is the largest global health financing contributor in the fight against HIV/AIDS, Tuberculosis and Malaria. Since its foundation in 2002, it approved funding for over US$ 24 billion through more than 570 programmes in more than 150 countries. It provides more than 25% of all international financing for AIDS, 65% for tuberculosis and 75% for malaria globally.

The fight against communicable diseases, and in particular HIV/AIDS, TB and Malaria, belong to the core priorities of SDC health policy and respective strategies at the level of HQ and countries related to health.

Switzerland has actively contributed at Board and Committee level to the successful implementation of the Reform (governance and grant management (NFM) aspects) in 2012 through targeted statements and interventions in collaboration with Canada as member of the constituency.

The following results can be reported:

1. More than 3.3 Mio people through ART treatment are saved
2. More than 8.6 Mio people are on TB treatment under DOTS
3. More than 230 Mio LLIN (treated mosquito nets) have been distributed

Despite the important initial decline of funding and reform of the GFATM in 2012, the Fund could guarantee the continuation of live saving activities to key population in all three diseases. The Reform was carried out according to plan in 2012 and with satisfactory results in terms of key population targeting, governance and future grant management which resulted into a New Funding Model NFM) and a more efficient way of doing business in the future.

Focused statements and interventions on

1. specific SDC health thematic priorities (eg. Malaria, HIV/AIDS and HSS) at the different level of the GFATM and other partners.
2. specific governance, grant and financial management topics at the different level of the GFATM

It can be expected that in 2012 and 2013 the number in terms of results for the three diseases has and will increase further (progress reports for the three diseases for 2012 will be available by June 2013). The expected efficient and fast track implementation of the NFM in 2013 as part of the new Strategy will represent a key element for the achievements of the agreed and expected results with the GFATM Strategy 2012-2016. The piloting phase of the NFM in 2013 which is linked to a rigorous M&E framework will allow strategic steering and adaptation for the next phases starting in 2014.

14

1. USA
2. France
3. England
4. Japan
5. Germany
6. Canada
7. European Commission
8. Sweden
9. Norway
10. Australia
11. Netherlands
12. Belgium
13. Denmark
14. Switzerland

Canada (Constituency member), P7 (Sweden, Irland, Danmark, Norway, Luxemburg), Germany EC (on specific topics only)

Phase 11 01.01.2014 - 31.12.2016   (Completed)